^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners

    TEST:
    UroSEEK

    Company:
    Sidney Kimmel Comprehensive Cancer Center
    Type:
    Laboratory Developed Test
    Details
    Evidence

    News

    1year
    Strategies for improving the chronic in-vivo integration of SiNAPS neural probes and assessment of performances (Neuroscience 2023)
    This strategy is foreseen to yield a more favorable postsurgical environment, reducing the extent of FBR in a chronic setting. We will present insertion force measurements and other strategies, acting both on probe design and on the implantation protocol, with the aim to advance the reliability of chronically implanted SiNAPS probes.
    Preclinical
    |
    UroSEEK
    over3years
    TERT promoter mutation in genomic evolution of urothelial bladder cancer: phylogenetic tree model by algorithmic inference from cross-sectional data (AUA 2021)
    "By using algorithmic inference, we showed TERT promoter may play an important role in UBC tumorigenesis."
    TP53 (Tumor protein P53) • PIK3CA (Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha) • FGFR3 (Fibroblast growth factor receptor 3) • ARID1A (AT-rich interaction domain 1A) • TERT (Telomerase Reverse Transcriptase) • KMT2D (Lysine Methyltransferase 2D) • KDM6A (Lysine Demethylase 6A)
    |
    TP53 mutation • PIK3CA mutation • ARID1A mutation • TERT mutation • TERT promoter mutation
    |
    CancerSEEK • UroSEEK
    almost5years
    UroSEEK gene panel for bladder cancer surveillance. (PubMed, Transl Androl Urol)
    No abstract available
    Journal
    |
    UroSEEK
    5years
    Performance of novel non-invasive urine assay UroSEEK in cohorts of equivocal urine cytology. (PubMed, Virchows Arch)
    "Seven cases in the early detection cohort and 71 surveillance cases were detected at least 6 months prior to clinical diagnosis. Our results suggest a potential role for UroSEEK assay in guiding management of patients with atypical urine cytology if confirmed in future prospective trials."
    Journal
    |
    UroSEEK
    over5years
    Incidence and distribution of UroSEEK gene panel in a multi-institutional cohort of bladder urothelial carcinoma. (PubMed, Mod Pathol)
    "Significantly higher rates of TP53 and CDKN2A mutation rates (p = 0.005 and 0.035, respectively) were encountered in muscle-invasive bladder tumors compared with those of pT1 stage. The overwhelming majority of all investigated tumors showed at least one mutation among UroSEEK assay genes, confirming the comprehensive coverage of the panel and supporting its potential utility as a noninvasive urine-based assay."
    Journal • Clinical
    |
    HER-2 (Human epidermal growth factor receptor 2) • KRAS (KRAS proto-oncogene GTPase) • TP53 (Tumor protein P53) • PIK3CA (Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha) • FGFR3 (Fibroblast growth factor receptor 3) • HRAS (Harvey rat sarcoma viral oncogene homolog) • CDKN2A (Cyclin Dependent Kinase Inhibitor 2A)
    |
    PIK3CA mutation • FGFR3 mutation • CDKN2A mutation • PIK3CA amplification
    |
    UroSEEK